Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor responders

There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current oncology reports 2009, Vol.11 (1), p.37-44
Hauptverfasser:	Wesolowski, Robert, Budd, George Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy, Adjuvant - methods Clinical Trials as Topic Combined Modality Therapy Disease-Free Survival Female Humans Ki-67 Antigen - biosynthesis Magnetic Resonance Imaging Medicine Medicine & Public Health Neoadjuvant Therapy - methods Oncology Postoperative Period Prognosis Receptors, Estrogen - metabolism Trastuzumab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!